Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Intellia Therapeutics cash
Cash and short-term investments held at the end of each period.
Intellia Therapeutics's cash was $437.76M at Jun 30, 2026. For fiscal 2025 it was $449.88M, down 25.2% from the year before. Over ten years it grew 19.5% a year on average. The highest annual figure on record is $1.19B in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $449.88M | -25.2% |
| FY2024 | Dec 31, 2024 | $601.52M | -34.1% |
| FY2023 | Dec 31, 2023 | $912.22M | -23.5% |
| FY2022 | Dec 31, 2022 | $1.19B | +59.3% |
| FY2021 | Dec 31, 2021 | $748.69M | +25.3% |
| FY2020 | Dec 31, 2020 | $597.37M | +113.6% |
| FY2019 | Dec 31, 2019 | $279.73M | -10.9% |
| FY2018 | Dec 31, 2018 | $314.06M | -7.8% |
| FY2017 | Dec 31, 2017 | $340.68M | +24.8% |
| FY2016 | Dec 31, 2016 | $273.06M | +260.2% |
| FY2015 | Dec 31, 2015 | $75.82M | +670.1% |
| FY2014 | Dec 31, 2014 | $9.85M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $437.76M | -4.8% |
| Q1 FY2026 | Mar 31, 2026 | $375.99M | -25.4% |
| Q4 FY2025 | Dec 31, 2025 | $449.88M | -25.2% |
| Q3 FY2025 | Sep 30, 2025 | $511.04M | -22.3% |
| Q2 FY2025 | Jun 30, 2025 | $459.65M | -33.5% |
| Q1 FY2025 | Mar 31, 2025 | $503.75M | -36.3% |
| Q4 FY2024 | Dec 31, 2024 | $601.52M | -34.1% |
| Q3 FY2024 | Sep 30, 2024 | $658.11M | -23.0% |
| Q2 FY2024 | Jun 30, 2024 | $691.07M | -23.9% |
| Q1 FY2024 | Mar 31, 2024 | $791.29M | -15.2% |
| Q4 FY2023 | Dec 31, 2023 | $912.22M | -23.5% |
| Q3 FY2023 | Sep 30, 2023 | $854.79M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | $908.07M | +3.9% |
| Q1 FY2023 | Mar 31, 2023 | $933.54M | +9.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.19B | +59.3% |
| Q3 FY2022 | Sep 30, 2022 | $828.19M | +3.7% |
| Q2 FY2022 | Jun 30, 2022 | $874.28M | +65.3% |
| Q1 FY2022 | Mar 31, 2022 | $855.25M | +46.4% |
| Q4 FY2021 | Dec 31, 2021 | $748.69M | +25.3% |
| Q3 FY2021 | Sep 30, 2021 | $798.27M | +95.7% |
| Q2 FY2021 | Jun 30, 2021 | $529.02M | +21.1% |
| Q1 FY2021 | Mar 31, 2021 | $584.06M | +133.4% |
| Q4 FY2020 | Dec 31, 2020 | $597.37M | +113.6% |
| Q3 FY2020 | Sep 30, 2020 | $407.95M | +42.7% |
| Q2 FY2020 | Jun 30, 2020 | $436.80M | +61.1% |
| Q1 FY2020 | Mar 31, 2020 | $250.26M | +431.4% |
| Q4 FY2019 | Dec 31, 2019 | $279.73M | -10.9% |
| Q3 FY2019 | Sep 30, 2019 | $285.92M | -2.5% |
| Q2 FY2019 | Jun 30, 2019 | $271.10M | -11.3% |
| Q1 FY2019 | Mar 31, 2019 | $47.10M | -85.6% |
| Q4 FY2018 | Dec 31, 2018 | $314.06M | -7.8% |
| Q3 FY2018 | Sep 30, 2018 | $293.25M | +31.9% |
| Q2 FY2018 | Jun 30, 2018 | $305.54M | +26.8% |
| Q1 FY2018 | Mar 31, 2018 | $327.78M | +27.3% |
| Q4 FY2017 | Dec 31, 2017 | $340.68M | +24.8% |
| Q3 FY2017 | Sep 30, 2017 | $222.26M | -23.5% |
| Q2 FY2017 | Jun 30, 2017 | $241.05M | – |
| Q1 FY2017 | Mar 31, 2017 | $257.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $273.06M | – |
| Q3 FY2016 | Sep 30, 2016 | $290.62M | – |
See a number that looks wrong?